重组带状疱疹疫苗在50岁及以上人群中的真实世界有效性:Kaiser Permanente Hawaii回顾性队列研究
该回顾性队列研究利用Kaiser Permanente Hawaii电子健康记录数据库,评估重组带状疱疹疫苗(RZV)在50岁及以上免疫功能正常、无带状疱疹病史人群中预防带状疱疹(HZ)和带状疱疹眼病(HZO)的有效性。共纳入78 356名成年人,其中11 864人(15.1%)接种了两剂有效RZV。结果显示RZV对HZ有效性为83.5%(95%CI:74.9%–89.2%),对HZO有效性为93.3%(95%CI:48.7%–99.1%),但疫苗覆盖率较低。
要点
- RZV对50岁及以上人群带状疱疹的有效性为83.5%(95%CI:74.9%–89.2%)。
- RZV对带状疱疹眼病的有效性为93.3%(95%CI:48.7%–99.1%)。
- 接种两剂RZV者仅占15.1%,疫苗覆盖率低,需加强公共卫生推广。
核心结论
- RZV在美国临床试验之外的真实世界环境中对HZ和HZO均显示出高有效性。
- 疫苗覆盖率低,强调需通过公共卫生努力增加接种以降低HZ和HZO的疾病负担。
研究设计与样本
- 回顾性队列研究,使用Kaiser Permanente Hawaii去标识化电子健康记录数据库。
- 纳入2018年1月1日至2019年12月31日期间达到RZV接种年龄资格、免疫功能正常、无HZ病史且此前连续入组KPH≥365天的成年人。
- 共纳入78 356名成年人,其中11 864人(15.1%)接种了两剂有效RZV。
主要发现
- 接种组HZ发病率为325.6例/10万人年(95%CI:217.7–464.4),未接种组为1063.3例/10万人年(95%CI:1006.0–1122.8)。
- 接种组HZO发病率为11.9例/10万人年(95%CI:0.7–52.3),未接种组为72.1例/10万人年(95%CI:58.0–88.3)。
- RZV对HZ的有效性为83.5%(95%CI:74.9%–89.2%),对HZO的有效性为93.3%(95%CI:48.7%–99.1%)。
临床怎么用
- 在50岁及以上免疫功能正常、无HZ病史人群中,接种两剂RZV可显著降低HZ和HZO发病风险。
- 当前RZV覆盖率仅15.1%,公共卫生应加强接种推广以降低HZ和HZO相关疾病负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of herpes zoster (HZ) has been on the rise for decades in the United States. Clinical trials for the recombinant zoster vaccine (RZV) demonstrated vaccine efficacy of over 90% in preventing herpes zoster. However, there is limited information on its effectiveness outside of a clinical trial setting, as well as its effectiveness against herpes zoster ophthalmicus (HZO). METHODS: A de-identified electronic health records database from Kaiser Permanente Hawaii (KPH) was used to conduct this retrospective cohort study to assess the effectiveness of the recombinant zoster vaccine against HZ and HZO in immunocompetent, vaccine age-eligible individuals without a prior history of HZ, who were continuously enrolled in KPH for ≥365 days prior to becoming age-eligible for RZV between January 1, 2018, through December 31, 2019. RESULTS: A total of 78 356 adults were included in this study, with 11 864 (15.1%) adults receiving two valid doses of the recombinant zoster vaccine. The incidence rate of HZ was 325.6 (95% CI: 217.7 to 464.4) cases per 100 000 person-years in vaccinated persons compared to 1063.3 cases per 100 000 person-years (95% CI: 1006.0 to 1122.8) in the unvaccinated group. The incidence rate of HZO was 11.9 (95% CI: 0.7 to 52.3) cases per 100 000 person-years in the vaccinated group compared to 72.1 (95% CI: 58.0 to 88.3) in the unvaccinated group. RZV was 83.5% (95% CI: 74.9% to 89.2%) effective against HZ and 93.3% (95% CI: 48.7% to 99.1%) effective against HZO. CONCLUSIONS: RZV has demonstrated high effectiveness against both HZ and HZO outside of a clinical trial setting in the United States. Vaccine coverage is low, emphasizing the need for public health efforts to increase vaccination to reduce morbidity from HZ and HZO.
引用
- Sun Y, Jackson K, Dalmon CA, et al. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study. Vaccine. 2021. PMID: 34116874. doi:10.1016/j.vaccine.2021.05.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。